Osivax Announces Vaccination of Last Patient in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs 478 participants were enrolled across Australia Full immunogenicity and safety results expected in the second half of 2024 Lyon, France – March 26, 2024 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that …